References
- Sharma A, Kumar N, Parachuri N, et al. Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression. Eye (Lond). 2020 Mar;34(3):422–423.
- Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology. 2019 Aug;126(8):1141–1154.
- [cited 2022 Feb 02]. https://www.retinasociety.org/content/meetingarchive/2020/awh-carl-primary-analysis-results-of-the-phase-3-archway-trial-of-the-port-delivery-system-with-ranibizumab-(pds)-for-patients-with-neovascular-amd-(namd).pdf
- FDA approves port delivery system with ranibizumab for wet AMD. [ cited 2022Feb 02]. https://www.hcplive.com/view/fda-approves-port-delivery-system-ranibizumab-wet-amd
- Sharma A, Kumar N, Kuppermann BD, Re: Campochiaro, et al. The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154). Ophthalmology. 2019;126(11):e87–e88.
- Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 129(3): 295–307. 2022.
- Bantseev V, Schuetz C, Booler HS, et al. Evaluation of surgical factors affecting vitreous hemorrhage following port delivery system with ranibizumab implant insertion in a minipig model. Retina. 2020;40(8):1520–1528.